The antistaphylococcal pharmacodynamics of linezolid alone and in combination with doxycycline in an in vitro dynamic model

Journal of Chemotherapy

Volumn 23, Issue 3, 2011, Pages 140-144

  Smirnova, M V ^a   Strukova, E N ^a   Portnoy, Y A ^a   Dovzhenko, S A ^a   Kobrin, M B ^a   Zinner, S H ^b   Firsov, A A ^a  

^a GAUSE INSTITUTE OF NEW ANTIBIOTICS   (Russian Federation)

^b MOUNT AUBURN HOSPITAL   (United States)

Author keywords

Doxycycline; In vitro dynamic models; Linezolid; Pharmacodynamics

Indexed keywords

DOXYCYCLINE; LINEZOLID;

AREA UNDER THE CURVE; ARTICLE; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATE; CONTROLLED STUDY; DRUG POTENTIATION; DRUG SCREENING; IN VITRO STUDY; NONHUMAN; STAPHYLOCOCCUS AUREUS;

EID: 80052730847     PISSN: 1120009X     EISSN: 19739478     Source Type: Journal    
DOI: 10.1179/joc.2011.23.3.140     Document Type: Article

References (17)

1. Sahuquillo Arce JM, Colombo Gainza E, Gil Brusola A, Ortiz Estevez R, Cantón E, Gobernado M. In vitro activity of linezolid in combination with doxycycline, fosfomycin, levofloxacin, rifampicin and vancomycin against methicillin-susceptible Staphylococcus aureus. Rev Esp Quimioterap 2006; 19: 252-247.
2. Blaser J. Interactions of antimicrobial combinations in vitro: the relativity of synergism. Scan J Infect Dis Suppl 1990; 74: 71-79.
3. Jones RN, Ross JE, Fritsche TR, Sader HS. Oxazolidinone susceptibility patterns in 2004: report from the Zyvox Annual Appraisal of Potency and Spectrum (ZAAPS) Program assessing isolates from 16 nations. J An-timicrob Chemother 2006;57: 279-287.
4. Schito GC, Debbia EA, Pesce A. Susceptibility of respiratory strains of Staphylococcus aureus to fifteen antibiotics: results of a collaborative surveillance study (1992-1993). The Alexander Project Collaborative Group. J Antimicrob Chemother 1996; 38(Suppl A): 97-106.
5. Stalker DJ, Jungbluth GL. Clinical pharmacokinetics of linezolid, a novel oxazolidinone antibacterial. Clin Pharmacokinet 2003; 42: 1129-1140.
6. Agwuh KN, MacGowan A. Pharmacokinetics and pharmacodynamics of the tetracyclines including glycylcyclines. J Antimicrob Chemother 2006; 58: 256-265.
7. Strukova EN, Smirnova MV, Vostrov SN, Portnoy YA, Dovzhenko SA, Kobrin MB et al. Anti-staphylococcal effects of telavancin and vancomycin in in vitro simulations of the antibiotic pharmacokinetics. Clin Microbiol n-timicrob Chemother. 2009; 11: 56-65. (Rus)
8. Smirnova MV, Vostrov SN, Strukova EN, Dovzhenko SA, Kobrin MB, Portnoy YA et al. The impact of duration of antibiotic exposure on bacterial resistance predictions using in vitro dynamic models. J Antimicrob Chemother 2009; 64: 815-820.
9. Firsov AA, Shevchenko AA, Vostrov SN, Zinner SH. Inter- and intra-quinolone predictors of antimicrobial effect in an in vitro dynamic model: new insight into a widely used concept. Antimicrob Agents Chemother 1998; 42: 659-665.
10. Blaser J, Stone BB, Zinner SH. Two compartment kinetic model with multiple artificial capillary units. J Antimicrob Chemother 1985; 15(Suppl A): 131-137.
11. Firsov AA, Chernykh VM, Navashin SM. Quantitative analysis of antimicrobial effect kinetics in an in vitro dynamic model. Antimicrob Agents Chemother 1990; 34: 1312-1317.
12. Firsov AA, Vostrov SN, Shevchenko AA, Cornaglia G. Parameters of bacterial killing and re growth kinetics and antimicrobial effect examined in terms of area under the concentration-time curve relationships: action of ciprofloxacin against Escherichia coli in an in vitro dynamic model. Antimicrob. Agents Chemother 1997; 41: 1281-1287.
13. Zinner SH, Gilbert D, Lubenko IY, Greer K, Firsov AA. Selection of linezolid-resistant Enterococcus faecium in an in vitro dynamic model: protective effect of doxycycline. J Antimicrob Chemother 2008; 61: 629-663.
14. Smirnova M, Alferova I, Lubenko I, Portnoy Y, Zinner S, Firsov A. Bacterial strain-independent pharmacodynamics of linezolid/doxycycline combinations with Staphylococcus aureus: 5-day simulations using an in vitro dynamic model. Clin Microbiol Infect 2006; 12(Suppl. 4): Abstract P1519.
15. Oberdisse E, Hackenthal E, Kuschinsky K. Pharmakologie und Toxikologie. 3. Auflage. Berlin, Heidelberg, New York: Springer-Verlag, 2002.
16. Tallarida RJ. An overview of drug combination analysis with isobolograms. J Pharm Exp Ther 2006; 319: 1-7.
17. Firsov A, Smirnova M, Strukova E, Portnoy Y, Zinner S. Staphylococcal resistance studies using susceptible organisms supplemented with their resistant mutants: combined treatment with linezolid (LZD) and gentamicin (GEN) simulated in an in uirro dynamic model. 48th Intersci Conf Antimicrob Agents and Chemother 2010, Abstract Al-006.